港股异动 | 康诺亚-B(02162)涨近6% Ouro Medicines并购协议已完成 公司已收到2.57亿美元首付款

智通财经
Jun 12

智通财经APP获悉,康诺亚-B(02162)涨近6%,截至发稿,涨4.95%,报58.3港元,成交额7014.41万港元。

消息面上,近日,康诺亚-B发布公告,有关出售集团于Ouro Medicines的少数股权,2026年6月5日,集团NewCo合作企业Ouro Medicines通过该等公告披露的并购协议现已正式完成,集团已收到2.57亿美元首付款。

根据并购协议条款,吉利德以16.75亿美元首付款及最高5亿美元的潜在里程碑付款,收购了Ouro Medicines全部股权。集团获告知根据吉利德科学公司(吉利德)和Lakefront Biotherapeutics NV(“Lakefront”, Euronext & Nasdaq: LKFT,曾用名Galapagos)之间的安排,他们双方将平摊首付款(按惯例调整)及最高5亿美元的潜在里程碑付款。

作为Ouro Medicines的股东,集团获得约2.57亿美元首付款及有权获得最高约7000万美元里程碑付款。此外,集团与Ouro Medicines于2024年11月订立的独家许可协议继续有效,最高6.1亿美元的里程碑付款及销售净额的分层特许权使用费由吉利德与Lakefront履行。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10